Radiotherapy for patients with locoregional and oligometastatic relapses of prostate cancer after radical prostatectomy
暂无分享,去创建一个
[1] V. Matveev,et al. Prostate-specific antigen is a predictor of the efficacy of salvage radiation therapy in patients with recurrent prostate cancer after radical prostatectomy , 2019, Cancer Urology.
[2] V. Matveev,et al. Простатспецифический антиген – предиктор эффективности спасительной лучевой терапии больных с рецидивами рака предстательной железы после радикальной простатэктомии , 2019 .
[3] Ситдиков Айрат Габитович,et al. Об основных итогах научной деятельности института археологии им. А. Х. Халикова Академии наук Татарстана в 2017 году , 2018 .
[4] Суконко Олег Григорьевич,et al. Рак предстательной железы у пациентов с метаболическими нарушениями , 2020 .
[5] Владимир Борисович Матвеев,et al. «Спасительная» лучевая терапия после радикальной простатэктомии с использованием последних достижений в радиационной онкологии , 2018 .
[6] Henry Knipe,et al. Oligometastases , 2016, Radiopaedia.org.
[7] S. Fanti,et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.
[8] M. Schwaiger,et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.
[9] F. Montorsi,et al. Natural history of surgically treated high-risk prostate cancer. , 2015, Urologic oncology.
[10] N. Corcoran,et al. Advances in local and ablative treatment of oligometastasis in prostate cancer , 2014, Asia-Pacific journal of clinical oncology.
[11] A. Kawashima,et al. Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging. , 2014, The Canadian journal of urology.
[12] Артемов Артем Викторович,et al. Применение митомицина в лечении рубцовых осложнений после радикальной простатэктомии , 2014 .
[13] C. Pelizzari,et al. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. , 2013, International journal of radiation oncology, biology, physics.
[14] P. Gabriele,et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging , 2009, European Radiology.
[15] Roberto Passariello,et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. , 2008, European urology.
[16] M. Kattan. Re: Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy gleason score (Partin Tables) based on cases from 2000 to 2005. , 2007, European urology.
[17] Alan W Partin,et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.
[18] Matthias D Hofer,et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.
[19] K. Haustermans,et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. , 2007, European urology.
[20] Anthony V D'Amico,et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. , 2007, The Journal of urology.
[21] M. Kattan,et al. Management of prostate‐specific antigen relapse in prostate cancer: A European consensus , 2004, International journal of clinical practice.